At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the interim analysis of PROCEDE−1000, a prospective registry evaluating the impact of Prolaris®, a cell cycle progression (CCP) test, on personalising treatment decisions following biopsy in newly diagnosed patients with prostate cancer.
Registry evaluating the impact of genomic testing on treatment of prostate cancer patients
26th August 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now